Alto Neuroscience (NYSE:ANRO) Trading Down 8% After Earnings Miss

Alto Neuroscience, Inc. (NYSE:ANRO) shares were down 8% on Wednesday after the company announced weaker than expected quarterly earnings. The company traded as low as $23.15 and last traded at $22.6620. Approximately 36,225 shares traded hands during trading, a decline of 86% from the average daily volume of 268,309 shares. The stock had previously closed at $24.63.

The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24).

Analysts Set New Price Targets

ANRO has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Alto Neuroscience in a report on Monday. Bank of America began coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Wedbush dropped their price target on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, April 2nd. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Finally, JonesTrading cut their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research report on Thursday, April 2nd. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $35.13.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new stake in shares of Alto Neuroscience during the 1st quarter worth $52,000. Torren Management LLC acquired a new stake in Alto Neuroscience in the 4th quarter valued at approximately $62,000. Invesco Ltd. purchased a new position in Alto Neuroscience in the first quarter worth approximately $67,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company’s stock valued at $69,000 after acquiring an additional 2,055 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in shares of Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after acquiring an additional 25,000 shares during the period.

Alto Neuroscience Stock Performance

The company has a quick ratio of 15.69, a current ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $727.12 million, a price-to-earnings ratio of -10.39 and a beta of 1.62. The firm has a fifty day moving average of $23.09 and a 200-day moving average of $18.29.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.